Masayuki Nakajima

Masayuki Nakajima

Auto-generated profile, based on publicly available information

Masayuki Nakajima

Department of Pulmonary Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
HSHirofumi Sakurai
Hirofumi Sakurai
YMYuko Morishima
Yuko Morishima
YIYukio Ishii
Yukio Ishii
KYKazufumi Yoshida
Kazufumi Yoshida
MNMasayuki Nakajima
Masayuki Nakajima
NHNobuyuki Hizawa
Nobuyuki Hizawa

1 January 2016 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MNMasayuki Nakajima
Masayuki Nakajima
NUNaoki Uchiyama
Naoki Uchiyama
RSRie Shigemasa
Rie Shigemasa
TMTakeshi Matsumura
Takeshi Matsumura
RMRyota Matsuoka
Ryota Matsuoka
ANAkihiro Nomura
Akihiro Nomura
This is the first report in which crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, reduced an atypical carcinoid tumor with ALK rearrangement. A 70-year-old man developed a tumor in the left lung and multiple metastases to the lung and brain. The pathology of transbronchial biopsied specimens demonstrated an atypical carcinoid pattern. Combined with immunohistochemical findings, we diagnosed the tumor as atypical carcinoid. ALK gene rearrangement was observed by both immunohistochemical (IHC) and fluorescence in situ hybridization. He was treated with chemotherapy as first-line therapy, however, the tumor did not respond to chemotherapy. Thereafter, he was treated with crizotinib, which successfully reduced the tumors.

1 February 2021 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MNMasayuki Nakajima
Masayuki Nakajima
MMMasashi Matsuyama
Masashi Matsuyama
NANaoki Arai
Naoki Arai
HYHideyasu Yamada
Hideyasu Yamada
KHKentaro Hyodo
Kentaro Hyodo
NHNobuyuki Hizawa
Nobuyuki Hizawa

30 December 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KYKazufumi Yoshida
Kazufumi Yoshida
YMYuko Morishima
Yuko Morishima
SASatoshi Ano
Satoshi Ano
HSHirofumi Sakurai
Hirofumi Sakurai
KKKenya Kuramoto
Kenya Kuramoto
NHNobuyuki Hizawa
Nobuyuki Hizawa

3 March 2017 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
MNMasayuki Nakajima
Masayuki Nakajima
MKMio Kawaguchi
Mio Kawaguchi
KOKyoko Ota
Kyoko Ota
JFJunichi Fujita
Junichi Fujita
SMSatoshi Matsukura
Satoshi Matsukura
NHNobuyuki Hizawa
Nobuyuki Hizawa
Introduction Interleukin (IL)‐17F plays a critical role in the pathophysiology of asthma. However, the precise role of IL‐17F in airway smooth muscle cells (ASMCs) and its regulatory mechanisms remain to be defined. Therefore, we sought to investigate the expression of IL‐6 by IL‐17F and the involvement of transforming growth factor β‐activated kinase 1 (TAK1) and nuclear factor (NF)‐κB by in ASMCs. Methods ASMCs were cultured in the presence or absence of IL‐17F. The expression of IL‐6 gene and protein was analyzed using real‐time PCR and ELISA, and the activation of TAK1 and NF‐κB was detected by Western blotting. The effect of TAK1 inhibitor 5Z‐7‐oxozeaenol and NF‐κB inhibitor BAY 11‐7082 on the expression of IL‐6 was investigated. Finally, the short interfering RNAs (siRNAs) targeting TAK1 and a subunit of NF‐κB, p65 were transfected into ASMCs. Results The expression of IL‐6 gene and protein was significantly induced by IL‐17F. IL‐17F activated TAK1 and NF‐κB in ASMCs. Transfection of siRNAs targeting TAK1 abolished IL‐17F‐induced phosphorylation of p65. Both 5Z‐7‐oxozeaenol and BAY 11‐7082 significantly inhibited IL‐17F‐induced IL‐6 production in a dose‐dependent manner. Similarly, transfection of the cells with siRNAs targeting TAK1 and p65 inhibited the expression of IL‐6. Conclusions Collectively, these results provided evidence supporting the potential importance of the Th17‐ASMCs crosstalk via the IL‐17F‐IL‐6 axis in airway inflammation and as a candidate pharmacological target for airway inflammatory diseases such as asthma.

1 March 2007 in Journal of Trauma: Injury, Infection & Critical Care
Verified
Journal Article
Closed access
SKShuhei Komatsu
Shuhei Komatsu
TSTakumi Shimomatsuya
Takumi Shimomatsuya
TKTaketsune Kobuchi
Taketsune Kobuchi
MNMasayuki Nakajima
Masayuki Nakajima
HAHirokazu Amaya
Hirokazu Amaya
KMKazuhiro Maruhashi
Kazuhiro Maruhashi